NCT07055568View on ClinicalTrials.gov

A Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Allogeneic iNKT Cell Infusion in Subjects With Advanced Pancreatic Cancer

NANot yet recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

January 30, 2028

Conditions
Pancreatic Cancer
Interventions
DRUG

iNKT

iNKT: Intravenous infusion, 0.5×10\^8cell-3.0×10\^8 cell

All Listed Sponsors
lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER